Adobe Reader is required to view these files. Adobe Reader is distributed free of charge by Adobe Systems Incorporated.
HOME > Investor Relations > IR Library > Financial Results > Financial Results 2003
Financial Results 2003
Financial Results for the Fiscal 2003 (April 1, 2003-March 31, 2004)
Financial Statements
- Financial Statements (entire file)
- Consolidated Financial Results for Fiscal 2003 and Forecasts for Fiscal 2004
- Group Organization
- Management Policies
- Operating Results and Financial Position
- Consolidated Financial Statements
- Summary of Significant Accounting Policies Used in Preparation of Consolidated Financial Statements
- Segment Information
- Marketable Securities
- Production, Orders and Sales
- Non-Consolidated Financial Statements for the Fiscal Year Ended March 31, 2004
- Non-Consolidated Balance Sheets
- Non-Consolidated Statements of Income
- Non-Consolidated Statements of Retained Earnings
- Summary of Significant Accounting Policies Used in Preparation of Non-Consolidated Financial Statements"Notes"Transfer of Officers
Reference Data
- Reference Data (entire file)
- Consolidated Financial Data
- Consolidated P/L Statement
- Consolidated Sales by Breakdown and Operating Income by Category
- Sales of Leading Products OTC and PD
- Capital Expenditure (Breakdown by Area)
- Subsidiaries and Affiliates
- Non-consolidated Financial Data
- Non-consolidated P/L Statement
- Non-consolidated Sales Breakdown by Category
- Sales of Leading Products OTC"Quasi-durg and LipoD Sales Breakdown by Channel
- Non-consolidated Sales Breakdown by Therapeutic Category"Capital Expenditure" Top 10 Shareholders
- New Drug Pipeline
- Launch of New Products (OTC)
- Brief Report of Consolidated Fiscal Results
- Consolidated Balance Sheets
- Consolidated Statements of Income
- Consolidated Statements of Retained Earnings
- Consolidated Statements of Cash Flows
Financial Results for the Third Quarter of Fiscal 2003 (April 1,-December 31, 2003)
Financial Results for the First Half of Fiscal 2003 (April 1,-September 30, 2003)
Financial Statements
- Financial Statements (entire file)
- Consolidated Financial Results for First Half of Fiscal 2003 and Forecasts for Fiscal 2003
- Group Organization
- Management Policies
- Operating Results and Financial Position
- Interim Consolidated Financial Statements
- Summary of Significant Accounting Policies Used in Preparation of Interim Consolidated Financial Statements
- Segment Information
- Marketable Securities
- Production, Orders, and Sales
- Non-Consolidated Financial Results for First Half of Fiscal 2003 and Forecasts for Fiscal 2003
- Non-Consolidated Financial Statements
- Summary of Significant Accounting Policies Used in Preparation of Non-Consolidated Financial Statements
Reference Data
- Reference Data (entire file)
- Consolidated Financial Data
- Consolidated P/L Statement
- Consolidated Sales by Category and Operating Income by Category
- Sales of Leading Products OTC and PD
- Capital Expenditure Breakdown by Area
- Subsidiaries and Affiliates
- Non-consolidated Financial Data
- Non-consolidated P/L Statement
- Non-consolidated Sales Breakdown by Category
- Sales of Leading Products OTC, Quasi-drug Drinks and Lipo Sales Breakdown by Channel
- Non-consolidated Sales Breakdown by Therapeutic Category"Capital Expenditure" Top 10 Shareholders
- New Drug Pipeline(domestic)
- New Drug Pipeline(overseas)
- Launch of New Products (OTC)
Financial Results for the First Quarter of Fiscal 2003 (April 1,-June 30, 2003)
